Pharmaceutical Executive Daily
New research suggests Ozempic may reduce biological age.
Recent Approvals and Acquisitions
The FDA has approved Bayer's Lynkuet for menopausal hot flashes.
- Lynkuet is the first dual neurokinin 1 and 3 receptor antagonist.
- It provides a non-hormonal option for patients with menopausal symptoms.
Novartis has a $12 billion merger agreement to acquire Avidity Biosciences.
New research suggests Ozempic may reduce biological age.
Author's summary: Ozempic may reduce biological age, new FDA approval.
More News
- Quantum Threats Demand Post-Quantum Cryptography Now
- CSL Earnings Slashed Amidst Vaccination Decline - Sharecafe
- Ranji Trophy 2025/26The Shillong Times
- Richard White targeted as federal police raid WiseTech
- Missed the Tracking and Fleet Monitoring webinar? Don't worry, you can still watch it!
- Massive shake-up for Whangarei finale
- Tariffs Shake Canadian Produce Supply Chain
- In Anish Kapoor’s Hands, an Offshore Gas Rig Became a Call for Climate Accountability